Impact of vericiguat on baroreflex-mediated sympathetic circulatory regulation: An open-loop analysis

Abstract

Aims

To quantify in vivo the effects of the soluble guanylate cyclase (sGC) stimulator, vericiguat, on autonomic cardiovascular regulation in comparison with the nitric oxide (NO) donor, sodium nitroprusside.

Methods

In anesthetized Wistar–Kyoto rats, baroreflex-mediated changes in sympathetic nerve activity (SNA), arterial pressure (AP), central venous pressure (CVP), and aortic flow (AoF) were examined before and during the intravenous continuous administration (10 μg·kg⁻¹·min⁻¹) of vericiguat or sodium nitroprusside (n = 8 each). Systemic vascular resistance (SVR) was calculated as SVR = (AP–CVP) / AoF.

Results

Neither vericiguat nor sodium nitroprusside affected fitted parameters of the baroreflex-mediated SNA response. Both vericiguat and sodium nitroprusside decreased the AP mainly through their peripheral effects. Vericiguat halved the slope of the SNA–SVR relationship from 0.012 ± 0.002 to 0.006 ± 0.002 mmHg·min·mL⁻¹·%⁻¹ (P = 0.008), whereas sodium nitroprusside caused a near parallel downward shift in the SNA–SVR relationship with a reduction of the SVR intercept from 1.235 ± 0.187 to 0.851 ± 0.123 mmHg·min/mL (P = 0.008).

Conclusion

Neither vericiguat nor sodium nitroprusside significantly affected the baroreflex-mediated SNA response. The vasodilative effect of vericiguat became greater toward high levels of SNA and AP, possibly reflecting the increased sGC sensitivity to endogenous NO. By contrast, the effect of sodium nitroprusside was more uniform over the range of SNA. These results help better understand cardiovascular effects of vericiguat.

Introduction

Nitric oxide (NO) produced by vascular endotherial cells reaches vascular smooth muscles and stimulates soluble guanylate cyclase (sGC), which increases cyclic guanosine monophosphate (cGMP) to dilate the vasculature. In cardiovascular diseases such as heart failure, reactive oxygen species (ROS) reduce NO production and promote myocardial and vascular damage resulting in further deterioration of the disease condition [1]. Although NO donors supply NO to stimulate the NO-sGC-cGMP pathway, organic nitrates such as nitroglycerin can induce NO tolerance [2, 3]. Sodium nitroprusside (SNP) spontaneously liberates NO but can also induce NO tolerance [4, 5]. The short half-life of SNP makes it appropriate for use as an acute therapy but hinders its chronic application. sGC stimulators and activators are a new class of drugs that directly act on sGC, an emerging therapeutic target for cardiopulmonary disease [6]. The sGC stimulators bind to NO-sensitive heme-containing sGC, whereas the sGC activators bind to NO-insensitive heme-free sGC. The sGC stimulators can act independently of NO and also in synergy with NO [7, 8]. Several clinical trials have shown benefits of vericiguat, a sGC stimulator, in patients with heart failure [9–11].

The treatment of heart failure has improved and the standard of care has updated, but the prognosis of heart failure remains unfavorable. There is a requirement for better heart failure treatment. It has been reported that the major event preceding the deterioration of recurrent heart failure is a significant increase in systemic vascular resistance (SVR) [12]. Decreasing SVR in heart failure lowers cardiac afterload, leading to increased cardiac output and peripheral perfusion [13, 14]. Mandry et al. reported that increased ejection fraction was associated with decreased SVR [14]. According to Follmann et al., vericiguat blocks contraction of isolated arteries in normal and nitrate-tolerant rabbits [7]. Vericiguat may alleviate the increase of SVR in vivo as a vasodilator.

Although vasodilation is expected from its key mechanism of action, whether or not vericiguat significantly modifies autonomic cardiovascular regulation in vivo remains to be quantitatively analyzed. The sympathetic limb of the autonomic nervous system plays a critical role in controlling SVR. Under normal physiological conditions, a decrease in arterial pressure (AP) increases sympathetic nerve activity (SNA) via the arterial baroreflex. Hence, the vasodilative effect of a given drug is partly counterbalanced by the baroreflex-mediated, sympathetic vasoconstriction. To circumvent such a confounding negative feedback effect, we have applied a framework of an open-loop analysis to the carotid sinus baroreflex system [15]. In this framework, the carotid sinus baroreflex system is divided into two principal subsystems: the neural arc subsystem, which represents the input–output relationship between baroreceptor pressure inputs and SNA, and the peripheral arc subsystem, which represents the relationship between SNA and AP [16]. The aim of the present study is twofold: 1) to quantify the vasodilative effect of vericiguat at different levels of SNA, and 2) to elucidate the effect of vericiguat on baroreflex-mediated regulation of SNA. Moreover, the effects of vericiguat on sympathetic cardiovascular regulation were compared with those of SNP.

Materials and methods

This study conforms to the "Guiding Principles for the Care and Use of Animals in Physiological Sciences" approved by the Japanese Physiological Society. All experimental protocols were reviewed and approved by the Animal Subjects Committee of the National Cardiovascular Center (No. 21009, 22033). Male Wistar–Kyoto rats were purchased from Japan SLC.

Preparation

Each rat was anesthetized by intraperitoneal injection (2 mL/kg) of a mixed anesthetic of urethane (250 mg/mL) and α-chloralose (40 mg/mL) and artificially ventilated with oxygenated air. A venous catheter was inserted into the left femoral vein and advanced to the inferior vena cava to measure central venous pressure (CVP). Another venous line was inserted from the right femoral vein for drug administration. A catheter-tip micromanometer (SPR-320, Millar, USA) was introduced from the right common carotid artery to measure AP. Heart rate (HR) was detected from a body surface electrocardiogram (AT-601G, Nihon Kohden, Japan). The anesthetic mixture was diluted 18-fold with physiological saline and administered continuously (2–3 mL·kg⁻¹·h⁻¹) to maintain anesthesia. Ringer’s lactate solution was infused (4 mL·kg⁻¹·h⁻¹) throughout the experiment to maintain fluid balance. The body temperature of the rats was maintained between 37°C and 38°C using a warming mat and a lamp.

Through a left flank incision, a pair of stainless-steel wire electrodes (AS633, Cooner Wire, USA) were attached to the postganglionic branch of the splanchnic sympathetic nerve. The nerve and electrodes were fixed and insulated with silicone adhesive (Kwik-Sil, World Precision Instruments, USA). The electrical signal was amplified using a biological amplifier and band-pass filtered between 150 and 1,000 Hz (AB-610J, Nihon Kohden, Japan). The signal was then full-wave rectified and low-pass filtered with a cut-off frequency of 30 Hz to quantify SNA. At the end of the experiment, a ganglionic blocker, hexamethonium bromide (FUJIFILM Wako Pure Chemical, Japan), was injected intravenously (60 mg/kg) to confirm SNA disappearance and determine the noise level.

The carotid sinus baroreceptor areas were isolated from the systemic circulation [17, 18], and carotid sinus pressure (CSP) was controlled using a servo-pump system (ET-126, Labworks, USA). To minimize reflex effects from the cardiopulmonary region and the aortic arch, the vagal nerves and the depressor nerves were sectioned in the neck region. Following the baroreceptor isolation, a flow probe (MA-2PSB, Transonic Systems, USA) was placed around the ascending aorta through a midline thoracotomy to measure aortic flow (AoF) (TS-420, Transonic Systems, USA).

Protocol

CSP was first decreased to 60 mmHg for 5 minutes, then increased stepwise in increments of 20 mmHg every minute to 180 mmHg. The 11-min CSP input sequence was repeated and designated as S1 through S4. From 1 minute after the completion of S2, an intravenous continuous administration of vericiguat or SNP was started.

Vericiguat protocol (n = 8 rats, 345–380 g): Vericiguat (BAY 1021189, MedChemExpress, USA) was dissolved with dimethyl sulfoxide (DMSO, FUJIFILM Wako Pure Chemical Corporation, Japan) at 1 mg/100 μL, and diluted with 1:1 volume of polyethylene glycol 200 and physiological saline to obtain the solution of 600 μg·kg⁻¹·mL⁻¹. The infusion rate was 1 mL/h, achieving the dose of 600 μg·kg⁻¹·h⁻¹ (10 μg·kg⁻¹·min⁻¹ or 23.5 nmol·kg⁻¹·min⁻¹). Because there was little available information on the use of vericiguat for continuous intravenous administration in rats, the dose used was adopted from the high dose of BAY 41–2272 (an agonist for sGC) used in anesthetized dogs [19]. The infusion volume was counterbalanced by reducing the infusion rate of the Ringer’s lactate solution by 1 mL/h.

SNP protocol (n = 8 rats, 326–385 g): SNP (Maruishi Pharmaceutical, Japan) was purchased as a solution of 3 mg/mL, and a regime comparable to vericiguat was adopted; i.e., 100 μL of DMSO was added per 1 mg of SNP, and diluted with 1:1 volume of polyethylene glycol 200 and physiological saline to the concentration of 600 μg·kg⁻¹·mL⁻¹ (10 μg·kg⁻¹·min⁻¹ or 33.6 nmol·kg⁻¹·min⁻¹). This solution was infused at 1 mL/h while the infusion rate of Ringer’s lactate solution was reduced by 1 mL/h.

Data analysis

Data were digitized with a 16-bit analog-to-digital converter (AIO AD16-16(PCI)EV, Contec, Japan) and recorded at 1,000 Hz on a laboratory computer system using custom-made software. The SNA, AP, HR, AoF, and CVP signals for the last 10 s of each CSP step (from 49 to 59 s to be exact) were averaged to obtain steady-state response values at each CSP level. Because the absolute amplitude of SNA varied depending on recording conditions across animals, the SNA was standardized in each animal based on values at CSP of 60 mmHg during S2 (100%) and after ganglionic blockade (0%). SVR was calculated from SVR = (AP–CVP) / AoF.

The AP, HR, and SNA responses as a function of CSP were quantified using the following 4-parameter logistic function [20].

(1)where y is the output variable; P₁, P₂, P₃, and P₄ are the response range, slope coefficient, midpoint pressure on the CSP axis, and lower limit of the sigmoid curve, respectively. The AP, SVR, and AoF as a function of SNA were quantified using linear regression.

(2)where y is the output variable. The baroreflex equilibrium diagram was obtained by plotting the neural arc (CSP–SNA relationship) and peripheral arc (SNA–AP relationship) on the plane of pressure versus SNA (Fig 1) [21–23]. The operating point of the carotid sinus baroreflex was determined from the intersection of the neural and peripheral arcs on the baroreflex equilibrium diagram.

[Figure omitted. See PDF.]

The baroreflex equilibrium diagram is obtained by plotting the neural arc (CSP–SNA relationship) and peripheral arc (SNA–AP relationship) on the plane of pressure versus SNA. The operating point of the carotid sinus baroreflex is determined from the intersection of the neural and peripheral arcs on the baroreflex equilibrium diagram.

Statistical analysis

Data are presented as mean ± SE values. In each drug protocol, the data during S2 served as baseline, and the drug effect was evaluated using the data during S4. Parameters were compared between S2 and S4 using the Wilcoxon signed-rank test [24]. The differences were considered statistically significant when P < 0.05.

Results

Fig 2 represents typical time series obtained from the vericiguat protocol. Under the baseline conditions (S2), an increase in CSP decreased SNA, AP, HR, and mean AoF (m-AoF). CVP did not change significantly with the increase in CSP, and the CVP response was not consistent among animals. From 1 min after the completion of S2, the intravenous continuous administration of vericiguat was started. The highest AP during low levels of CSP was decreased in S4 compared with that in S2. The SNA and HR responses were not much different between S2 and S4. The m-AoF slightly increased in S4 compared with that in S2.

[Figure omitted. See PDF.]

CSP was changed in a stepwise manner with a step duration of 60 s. The input sequence was repeated and designated as S1 through S4. An increase in CSP decreased SNA, AP, HR, and m-AoF. CVP did not change significantly with the increase in CSP. From 1 min after the completion of S2, an intravenous administration of vericiguat was started and continued throughout the end of the protocol. The effect of vericiguat was evaluated in S4. Vericiguat decreased AP without significant changes in the SNA and HR responses. The CSP and HR are presented as 10-Hz resampled signals. The green and yellow lines in the SNA plot indicate 10-Hz resampled and 2-s moving averaged signals, respectively. The red and yellow lines in the AP plot indicate 100-Hz resampled and 2-s moving averaged signals, respectively. The m-AoF is presented as 2-s moving averaged signals. CSP, carotid sinus pressure; SNA, sympathetic nerve activity; AP, arterial pressure; HR, heart rate; m-AoF, mean aortic flow; CVP, central venous pressure.

Fig 3 and Table 1 summarize the effects of vericiguat on the baroreflex-mediated responses. Vericiguat significantly narrowed the range of the AP response (P₁) and decreased the lower limit of the sigmoid curve (P₄) in the total arc (Fig 3A), whereas it did not significantly affect the CSP–HR relationship (Fig 3B) or the neural arc (Fig 3C). Vericiguat significantly decreased the slope of the peripheral arc (Fig 3D) with a reduction in the slope of the SNA–SVR relationship (Fig 3E) and slight increases in the slope and intercept of the SNA–AoF relationship (Fig 3F). Vericiguat marginally increased the averaged CVP (Fig 3G). On the baroreflex equilibrium diagram (Fig 3H), the intersection between the neural and peripheral arcs gives the operating point. Vericiguat significantly decreased the AP at the operating point due to the reduction in the slope of the peripheral arc.

[Figure omitted. See PDF.]

Group-averaged relationships of the total arc (A), CSP–HR relationship (B), neural arc (C), peripheral arc (D), SNA–SVR relationship (E), SNA–AoF relationship (F), CSP–CVP relationship (G), and the baroreflex equilibrium diagram constructed from the mean curve of the neural arc and the mean line of the peripheral arc (H) in the vericiguat protocol. In panels A–G, the data points are presented as mean ± SE values. In panel H, the operating point is displayed as mean ± SE values. P₁ and P₄ indicate the response range and the lower limit, respectively. The symbol * and ** indicate statistical significances at P < 0.05 and P < 0.01, respectively, by the Wilcoxon signed-rank test. In panel G, the P value was derived from the Wilcoxon signed-rank test. CSP, carotid sinus pressure; AP, arterial pressure; HR, heart rate; SNA, sympathetic nerve activity; SVR, systemic vascular resistance; AoF, aortic flow; CVP, central venous pressure; op-AP, AP at the operating point.

[Figure omitted. See PDF.]

Fig 4 represents typical time series obtained from the SNP protocol. Under the baseline conditions (S2), an increase in CSP decreased SNA, AP, HR, and m-AoF. CVP did not change significantly with the increase in CSP. From 1 min after the completion of S2, the intravenous continuous administration of SNP was started. The AP dropped acutely at the onset of the SNP administration. The highest AP during low levels of CSP was decreased in S4 compared with that in S2. The HR was slightly higher during S4 than during S2 in this rat, but this observation was not consistent across the group. SNP did not significantly affect the SNA or m-AoF response.

[Figure omitted. See PDF.]

CSP was changed in a stepwise manner with a step duration of 60 s. The input sequence was repeated and designated as S1 through S4. An increase in CSP decreased SNA, AP, HR, and m-AoF. CVP did not change significantly with the increase in CSP. From 1 min after the completion of S2, an intravenous administration of SNP was started and continued throughout the end of the protocol. The effect of SNP was evaluated in S4. SNP decreased AP without significant changes in the SNA and HR responses. The CSP and HR are presented as 10-Hz resampled signals. The green and yellow lines in the SNA plot indicate 10-Hz resampled and 2-s moving averaged signals, respectively. The red and yellow lines in the AP plot indicate 100-Hz resampled and 2-s moving averaged signals, respectively. The m-AoF is presented as 2-s moving averaged signals. CSP, carotid sinus pressure; SNA, sympathetic nerve activity; AP, arterial pressure; HR, heart rate; m-AoF, mean aortic flow; CVP, central venous pressure; SNP, sodium nitroprusside.

Fig 5 and Table 2 summarize the effects of SNP on the baroreflex-mediated responses. SNP significantly decreased P₁ and P₄ in the total arc (Fig 5A), whereas it did not significantly affect the CSP–HR relationship (Fig 5B) or the neural arc (Fig 5C). SNP caused a downward shift in the peripheral arc with reductions in the slope and intercept (Fig 5D). During the SNP administration, the SNA–SVR relationship showed a near parallel downward shift (Fig 5E), whereas the SNA–AoF relationship hardly changed (Fig 5F). SNP did not significantly affect the averaged CVP (Fig 5G). The baroreflex equilibrium diagram indicates that SNP significantly decreased the AP at the operating point due to the change in the peripheral arc (Fig 5H).

[Figure omitted. See PDF.]

Group-averaged relationships of the total arc (A), CSP–HR relationship (B), neural arc (C), peripheral arc (D), SNA–SVR relationship (E), SNA–AoF relationship (F), CSP–CVP relationship (G), and the baroreflex equilibrium diagram constructed from the mean curve of the neural arc and the mean line of the peripheral arc (H) in the SNP protocol. In panels A–G, the data points are presented as mean ± SE values. In panel H, the operating point is displayed as mean ± SE values. P₁ and P₄ indicate the response range and the lower limit, respectively. The symbol * and ** indicate statistical significances at P < 0.05 and P < 0.01, respectively, by the Wilcoxon signed-rank test. n.s., not significant by the Wilcoxon signed-rank test; CSP, carotid sinus pressure; AP, arterial pressure; HR, heart rate; SNA, sympathetic nerve activity; SVR, systemic vascular resistance; AoF, aortic flow; CVP, central venous pressure; op-AP, AP at the operating point; SNP, sodium nitroprusside.

[Figure omitted. See PDF.]

Discussion

Effects of vericiguat and SNP on the peripheral arc and SVR

Both vericiguat and SNP narrowed the range of the AP response and decreased the lower limit of the baroreflex total arc (Figs 3A and 5A). For both drugs, the AP reduction was primarily due to the downward change of the peripheral arc (Figs 3D and 5D). The change in the AP may be decomposed into changes in the SVR and AoF. Vericiguat halved the slope of the SNA–SVR relationship (Fig 3E), whereas SNP caused a near parallel downward shift in the SNA–SVR relationship (Fig 5E). Although both drugs act on the NO-sGC-cGMP pathway, the differential effects on the SNA–SVR relationship may be explained by differences in their modes of action. As mentioned in the Introduction, vericiguat acts independently of endogenous NO but also enhances sGC sensitivity to endogenous NO [7, 8, 25]. The endogenous NO production in the vascular endothelium increases at high AP levels because of the increased shear stress [26, 27]. Accordingly, the vasodilative effect of vericiguat might have become greater toward higher levels of AP and SNA (Fig 3E). It may also be possible that SNA augmented the NO-independent direct effect of vericiguat on the sGC-cGMP pathway. By contrast, SNP might have caused vasodilation irrespective of the levels of endogenous NO (Fig 3E). In an in vitro study, SNP showed a parallel rightward shift of the dose-response curve of the rat aorta to noradrenaline [28]. Although the lack of shear stress is a confounding factor in interpreting the results of the organ bath experiment, the parallel shift of the dose-response curve may be in line with the downward shift of the SNA–SVR relationship observed in the present study.

Vericiguat significantly increased the intercept and slope of the SNA–AoF relationship (Fig 3F). An afterload reduction by vasodilation might have contributed to the increased AoF because vericiguat has no significant effect on the ventricular contractility in rat heart Langendorff preparations [7]. By contrast, SNP hardly affected AoF (Fig 3F) despite the afterload reduction by vasodilation. Veins show greater sensitivity than arteries for SNP and nitroglycerin in the organ bath, though SNP exerts a more balanced effect on resistance and capacitance vessels in vivo [29]. In a canine right-heart bypass preparation [30], SNP decreased cardiac output under normal conditions because of the downward shift of the venous return curve. In the same study, induction of left ventricular failure by coronary occlusion caused a downward shift of the venous return curve. During the coronary occlusion, SNP did not significantly affect the venous return curve and increased cardiac output via afterload reduction. Hence, the balance between afterload reduction and preload reduction under a given set of conditions is a determinant of the effect of vasodilators on cardiac output. Vericiguat marginally increased the averaged CVP, whereas SNP did not. However, because we did not measure left ventricular function, we were unable to identify the exact mechanism for the differential effects of vericiguat and SNP on AoF.

There is limited clinical data demonstrating the impact of vericiguat on hemodynamics. In the VICTORIA trial [11], which showed the clinical benefits of vericiguat in HFrEF (heart failure with reduced ejection fraction) patients, the BP reduction in the vericiguat group was very small, which is considered one of the advantages of vericiguat over other guideline-directed medical therapies. The fact that vericiguat does not directly reduce SNA and increase cardiac output by decreasing LV afterload may help maintain BP. Meanwhile, in this study, vericiguat reduced BP by substantially decreasing SVR. The dose of vericiguat used in this experiment differed from the clinical dose and may have resulted in a greater reduction in SVR than in clinical situations. The daily dose of vericiguat is a maximum of 10 mg, which corresponds to 0.139 μg·kg⁻¹·min⁻¹ if we assume a body weight of 50 kg. Hence, the dose of 10 μg·kg⁻¹·min⁻¹ in the present study needs to be interpreted as a dose above the therapeutic range. In the SOCRATES-REDUCED trial [9], patients in the 10-mg vericiguat group experienced an increase in left ventricular ejection fraction. However, to our knowledge, there is no available data regarding the effect of vericiguat on cardiac output. As discussed above, the effect of a test drug could be determined by the balance between its vasodilative effects on arteries and veins.

Effects of vericiguat and SNP on the neural arc and HR response

Although sGC exists ubiquitously in the whole body including the central nervous system [31], neither vericiguat nor SNP acutely affected the neural arc. SNP has been used with phenylephrine to perturb the AP and estimate the baroreflex-mediated SNA and HR responses [32, 33]. The presumption for this method is that SNP does not directly modulate the central processing of the arterial baroreflex. The fact that there is no significant effect of SNP on the baroreflex neural arc (Fig 5C) ascertains that SNP is appropriate for use as a test drug for estimating baroreflex function.

Vericiguat has little ability to cross the blood-brain barrier (BBB) [34]; and thus, the finding of no significant effect of intravenous vericiguat on the neural arc (Fig 3C) might have been predicted. Nevertheless, low penetration across the BBB is not necessarily the same as absence of central effects of a given agent. As an example, plasma angiotensin II does not cross the BBB under normal conditions but exerts a central effect by acting on brain areas that reside outside the BBB, such as the subfornical organ and the area postrema [35]. High levels of circulating angiotensin II caused a near parallel upward shift in the baroreflex neural arc [36].

In the present experimental settings, the HR response to the CSP change was mediated by the sympathetic nervous system because of vagotomy. Hence, no significant effects of vericiguat and SNP on the CSP–HR relationship (Figs 3B and 5B) are consistent with the finding of no significant effects of these drugs on the baroreflex neural arc. Further, the results on the HR response suggest that neither vericiguat nor SNP has a significant direct effect on the sinoatrial node. Rat heart Langendorff preparations also indicate no significant effect of vericiguat on HR [7].

Limitations

Several limitations need to be mentioned. First, the experiment was performed on anesthetized rats, and careful interpretation is required when extrapolating the present results to conscious conditions and other species. Second, the drug effects were examined in normal rats. Because the level of endogenous NO may be decreased in diseased conditions, the effects of vericiguat and SNP on the peripheral arc in diseased conditions could be different from the present results. Studies using a rat model of myocardial infarction or Dahl salt-sensitive rats may be required to investigate the effects of vericiguat and SNP in chronic hyperadrenergic conditions. Third, only a single dose was tested in each protocol. There is room for argument that the difference in the SNA–SVR relationship between vericiguat and SNP could depend on the dose, and further studies focusing on the dose-response are warranted. Fourth, the intercept of SNA–SVR relationship under baseline was lower in the vericiguat protocol than in the SNP protocol for unknown reasons, which might have also affected the magnitude of the vasodilative effect. Finally, the first-in-class sGC stimulator riociguat was introduced as a novel treatment option for pulmonary hypertension [7]. We cannot find available literature regarding the effect of vericiguat on the vasodilative response of pulmonary arteries. Further studies are required to quantify the effect of vericiguat on the pulmonary vasculature.

Conclusions

The effects of vericiguat on the open-loop baroreflex static characteristics were estimated and compared with those of SNP. Neither vericiguat nor SNP significantly affected the neural arc, suggesting the limited effects of these drugs on the central regulation of the sympathetic nervous system. Both vericiguat and SNP decreased the AP mainly through their peripheral effects. The vasodilative effect of vericiguat became greater toward high levels of SNA and AP, possibly reflecting the increased sGC sensitivity to endogenous NO. By contrast, the effect of SNP was more uniform over the range of SNA. The systematic analysis using the baroreflex open-loop procedure would help understand cardiovascular effects of vericiguat.

Supporting information

S1 Data.

https://doi.org/10.1371/journal.pone.0286767.s001

(XLSX)

S2 Data.

https://doi.org/10.1371/journal.pone.0286767.s002

(XLSX)

S3 Data.

https://doi.org/10.1371/journal.pone.0286767.s003

(XLSX)

S4 Data.

https://doi.org/10.1371/journal.pone.0286767.s004

(XLSX)

Citation: Yokoi A, Kawada T, Yokota S, Kakuuchi M, Matsushita H, Nishiura A, et al. (2023) Impact of vericiguat on baroreflex-mediated sympathetic circulatory regulation: An open-loop analysis. PLoS ONE 18(8): e0286767. https://doi.org/10.1371/journal.pone.0286767

About the Authors:

Aimi Yokoi

Contributed equally to this work with: Aimi Yokoi, Toru Kawada

Roles: Data curation, Formal analysis, Investigation, Project administration, Validation, Visualization, Writing – original draft

Affiliations: Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan

ORICD: https://orcid.org/0000-0002-3124-912X

Toru Kawada

Contributed equally to this work with: Aimi Yokoi, Toru Kawada

Roles: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

E-mail: [email protected] (TK); [email protected] (KS)

Affiliation: Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

Shohei Yokota

Roles: Writing – review & editing

Affiliation: Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

Midori Kakuuchi

Roles: Writing – review & editing

Affiliation: Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

Hiroki Matsushita

Roles: Writing – review & editing

Affiliation: Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

ORICD: https://orcid.org/0000-0002-0367-2369

Akitsugu Nishiura

Roles: Writing – review & editing

Affiliation: Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

Meihua Li

Roles: Writing – review & editing

Affiliation: Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

Kazunori Uemura

Roles: Writing – review & editing

Affiliation: Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

Joe Alexander Jr

Roles: Supervision, Writing – review & editing

¶‡ JA and KS also contributed equally to this work.

Affiliation: Medical and Health Informatics, NTT Research, Inc., Sunnyvale, CA, United States of America

Ryou Tanaka

Roles: Writing – review & editing

Affiliation: Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan

ORICD: https://orcid.org/0000-0001-9948-6490

Keita Saku

Roles: Conceptualization, Data curation, Funding acquisition, Project administration, Supervision, Validation, Writing – review & editing

E-mail: [email protected] (TK); [email protected] (KS)

¶‡ JA and KS also contributed equally to this work.

Affiliation: Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

References

1. Sandner P, Stasch JP. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Resp Med 122: S1–S9, 2017. pmid:28341058

2. Münzel T, Daiber A, Mülsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 97: 618–628, 2005. pmid:16195486

3. França-Silva MS, Balarini C, Cruz JC, Khan BA, Rampelotto RH, Braga VA. Organic nitrates: past, present, and future. Molecules 19: 15314–15323, 2014. pmid:25255247

4. Papapetropoulos A, Go CY, Murad F, Catravas JD. Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells. Br J Pharmacol 117: 147–155, 1996. pmid:8825356

5. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide. An overview. Circ Res 90: 21–28, 2002. pmid:11786514

6. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123: 2263–2273, 2011. pmid:21606405

7. Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem 60: 5146–5161, 2017. pmid:28557445

8. Sandner P, Follmann M, Becker-Pelster E, Hahn MG, Meier C, Freitas C, et al. Soluble GC stimulators and activators: Past, present, and future. Br J Pharmacol 2021: 1–22, 2021. pmid:34600441

9. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA 314: 2251–2262, 2015. pmid:26547357

10. Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with preserved EF (SOCRATES-PRESERVED) study. Eur Heart J 38: 1119–1127, 2017. pmid:28369340

11. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382: 1883–1893, 2020. pmid:32222134

12. Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr Opin Cardiol 18: 215–222, 2003. pmid:12826823

13. Weldy CS, Ashley EA. Towards precision medicine in heart failure. Nat Rev Cardiol 18: 745–762, 2021. pmid:34108678

14. Mandry D, Girerd N, Lamiral Z, Huttin O, Filippetti L, Micard E, et al. Relationship between left ventricular ejection fraction variation and systemic vascular resistance: A prospective cardiovascular magnetic resonance study. Front Cardiovasc Med 8: 803567, 2021. pmid:35004914

15. Kawada T, Sugimachi M. Open-loop static and dynamic characteristics of the arterial baroreflex system in rabbits and rats. J Physiol Sci 66: 15–41, 2016. pmid:26541155

16. Ikeda Y, Kawada T, Sugimachi M, Kawaguchi O, Shishido T, Sato T, et al. Neural arc of baroreflex optimizes dynamic pressure regulation in achieving both stability and quickness. Am J Physiol 271: H882–H890, 1996. pmid:8853321

17. Shoukas AA, Callahan CA, Lash JM, Haase EB. New technique to completely isolate carotid sinus baroreceptor regions in rats. Am J Physiol 260: H300–H303, 1991. pmid:1992808

18. Sato T, Kawada T, Miyano H, Shishido T, Inagaki M, Yoshimura R, et al. New simple methods for isolating baroreceptor regions of carotid sinus and aortic depressor nerves in rats. Am J Physiol 276: H326–H332, 1999. pmid:9887047

19. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41–2272 in experimental congestive heart failure. Circulation 107: 686–689, 2003. pmid:12578869

20. Kent BB, Drane JW, Blumenstein B, Manning JW. A mathematical model to assess changes in baroreceptor reflex. Cardiology 57: 295–310, 1972. pmid:4651782

21. Mohrman DE, Heller LJ. Cardiovascular Physiology, 7th edn, McGraw-Hill, New York, p 246–250, 2010.

22. Sato T, Kawada T, Inagaki M, Shishido T, Takaki H, Sugimachi M, et al. New analytic framework for understanding sympathetic baroreflex control of arterial pressure. Am J Physiol 276: H2251–H2261, 1999. pmid:10362709

23. Yamasaki F, Sato T, Sato K, Diedrich A. Analytic and integrative framework for understanding human sympathetic arterial baroreflex function: equilibrium diagram of arterial pressure and plasma norepinephrine level. Front Neurosci 15: 707345, 2021. pmid:34335177

24. Glantz SA. Primer of Biostatistics, 7th edn. McGraw-Hill, 2012.

25. Aimo A, Castiglione V, Vergaro G, Panichella G, Senni M, Lombardi CM, et al. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail Rev 27: 1165–1171, 2022. pmid:34291399

26. Stauss HM, Persson PB. Role of nitric oxide in buffering short-term blood pressure fluctuations. News Physiol Sci 15: 229–233, 2000. pmid:11390916

27. Lu D, Kassab GS. Role of shear stress and stretch in vascular mechanobiology. J R Soc Interface 8: 1379–1385. 2011. pmid:21733876

28. Kreye VAW, Baron GD, Jüth JB, Schmidt-Gayk H. Mode of action of sodium nitroprusside on vascular smooth muscle. Naunyn-Schmiedeberg’s Ach Pharmacol 288: 381–402, 1975. pmid:170545

29. Stiefel A, Kreye VAW. On the haemodynamic differences between sodium nitroprusside, nitroglycerin, and isosorbide nitrates. Comparison of their vasorelaxant effects in vitro and of their inactivation in vivo. Naunyn-Schmiedeberg’s Arch Pharmacol 325: 270–274, 1984. pmid:6427631

30. Pouleur H, Covell JW, Ross J Jr. Effects of nitroprusside on venous return and central blood volume in the absence and presence of acute heart failure. Circulation 61: 328–337, 1980. pmid:7351058

31. Ding JD, Burette A, Nedvetsky PI, Schmidt HHHW, Weinberg RJ. Distribution of soluble guanylyl cyclase in the rat brain. J Comp Neurol 472: 437–448, 2004. pmid:15065118

32. Moffitt JA, Foley CM, Schadt JC, Laughlin MH, Hasser EM. Attenuated baroreflex control of sympathetic nerve activity after cardiovascular deconditioning in rats. Am J Physiol 274: R1397–405, 1998. pmid:9612408

33. Rudas L, Crossman AA, Morillo CA, Halliwill JR, Tahvanainen KU, Kuusela TA, et al. Human sympathetic and vagal baroreflex responses to sequential nitroprusside and phenylephrine. Am J Physiol 276: H1691–1698, 1999. pmid:10330255

34. Nelissen E, Argyrousi EK, Van Goethem NP, Zhao F, Hines CDG, Swaminath G, et al. Soluble guanylate cyclase stimulator vericiguat enhances long-term memory in rats without altering cerebral blood volume. Biomedicines 9: 1047, 2021. pmid:34440254

35. Biancardi VC, Son SJ, Ahmadi S, Filosa JA, Stern JE. Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier. Hypertension 63: 572–579, 2014: pmid:24343120

36. Kawada T, Kamiya A, Li M, Shimizu S, Uemura K, Yamamoto H, et al. High levels of circulating angiotensin II shift the open-loop baroreflex control of splanchnic sympathetic nerve activity, heart rate and arterial pressure in anesthetized rats. J Physiol Sci 59: 447–455, 2009. pmid:19688237